Bavarian Nordic
NEWS
A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has approved JYNNEOS™ for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
The vaccine is the only approved non-replicating smallpox vaccine in the U.S. and the only approved monkeypox vaccine anywhere in the world, the company said.
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN®for active immunization against smallpox in adults age 18 years and older.
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, OrbiMed and Brace Pharma Capital.
Award of approximately USD 37 million will support clinical work required for product approval.
JOBS
IN THE PRESS